Company
Rekover Therapeutics
- Business model
- B2B
Claim, correct or request removal
Record updated 28 September 2026
About
A lead program is advancing a drug aimed at remyelinating neurons in patients with multiple sclerosis with the potential to reverse the negative effects of neurodegeneration.
Loading relationship preview